Teva's 95.68% Volume Spike Propels Stock to 414th in Liquidity Amid Patent Expansion and Restructuring Moves

On Sept. 22, 2025, , . The surge followed renewed investor focus on the company’s patent portfolio expansion and potential regulatory milestones in its generic drug pipeline. Analysts noted that increased volume signaled short-term speculative positioning, though longer-term catalysts remain tied to its cost-cutting initiatives and restructuring progress.

Recent developments highlighted Teva’s strategic shift toward high-margin specialty generics, with a key partnership announcement expected in late Q3. , . While these moves have historically pressured sentiment, . No major litigation updates or product recalls were reported, which typically drive volatility in the sector.

To build an accurate back-test for “buy the top 500 stocks by daily trading volume, , . ? U.S. ? ? , ? ? ? .